Capital Fund Management (CFM)
MDGL icon

Capital Fund Management (CFM)’s Madrigal Pharmaceuticals MDGL Stock Holding History

Capital Fund Management (CFM)’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-15,762
Closed -$4.42M – 2085
2024
Q2 		$4.42M Buy
15,762
+3,237
+26% +$771K 0.01% 1010
2024
Q1 		$3.34M Sell
12,525
-8,649
-41% -$2.04M 0.01% 1218
2023
Q4 		$4.9M Buy
+21,174
New +$3.71M 0.01% 1100
2023
Q3 		– Sell
-18,205
Closed -$4.21M – 2029
2023
Q2 		$4.21M Buy
+18,205
New +$4.93M 0.02% 913

Other funds holding MDGL

Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
PC
Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Capital Fund Management (CFM)'s MDGL Position: Q3 2024 in Review

Capital Fund Management (CFM) sold out of Madrigal Pharmaceuticals (MDGL) in Q3 2024, closing a stake of 15,762 shares — an estimated $4.42M sold.

Capital Fund Management (CFM) first reported a position in MDGL in Q2 2023 and held it in 4 quarters. The position peaked at $4.9M in Q4 2023. 257 funds tracked by Wall St. Rank hold MDGL as of Q3 2024.

  • Capital Fund Management (CFM) reported no remaining Madrigal Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
  • Capital Fund Management (CFM) sold 15,762 Madrigal Pharmaceuticals shares in Q3 2024, an estimated $4.42M.
  • Capital Fund Management (CFM) first reported a position in Madrigal Pharmaceuticals in Q2 2023 and held it in 4 quarters.
  • Capital Fund Management (CFM)'s Madrigal Pharmaceuticals position peaked at $4.9M in Q4 2023.
  • 257 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q3 2024.

Based on Capital Fund Management (CFM)'s 13F filing for Q3 2024, filed 13 Nov 2024.